GSK's Ovarian and Uterine Cancer Drug Mo-Rez Draws Attention with BEHOLD-1 Data

Mo-Rez, a New Star of ADC Technology: Striking Response Rates in Resistant Ovarian and Uterine Cancer

Why Is It So Difficult? Resistance in Gynecologic Cancers

Ovarian cancer (cancer of the ovaries) and endometrial cancer (cancer of the uterine lining) are gynecologic malignancies in which treatment options narrow rapidly when diagnosed at an advanced stage or after recurrence. Worldwide, approximately 240000 women are diagnosed with ovarian cancer and more than 400000 with endometrial cancer each year.

Platinum-resistant ovarian cancer (PROC) is defined as disease progression within 6 months after initial treatment, and response rates with available chemotherapy options in this group generally remain around 10–15%. Similarly, response rates in endometrial cancer are limited when patients move to second- or third-line treatment. In this setting, 62% and 67% response rates represent not only a statistical success, but a real clinical gain for patients with limited options.

How Does Mo-Rez Work? The Anatomy of “Smart Bomb” Technology

Antibody-drug conjugates are one of the most exciting drug classes in modern oncology. This technology brings together three basic components: a target-specific antibody, a cytotoxic payload and a chemical linker connecting the two.

Mo-Rez's target, B7-H4, is a protein belonging to the family of immune-regulatory receptors (immune checkpoints). As stated in the BEHOLD-1 presentation, B7-H4 is expressed in more than 95% of ovarian and endometrial cancers; its expression in healthy tissues, by contrast, is very low. This difference makes B7-H4 an ideal therapeutic target: the drug's field of action has been narrowed and its safety window widened.

Trial Design: FDA-Aligned Methodology with Dose Optimization

BEHOLD-1 (NCT06431594) is a two-part, open-label, global Phase I trial. The first part (Phase Ia) involves dose escalation in advanced solid tumors, while the second part (Phase Ib), focusing on gynecologic cancers, includes a randomized comparison of three Mo-Rez doses.

In the PROC cohort, 131 patients were randomized equally to three dose arms (2.8 mg/kg, 4.8 mg/kg and 5.8 mg/kg, every 3 weeks). In the endometrial cancer cohort, 49 patients were randomized to two dose arms (2.8 mg/kg and 4.8 mg/kg). This randomized dose-evaluation design directly meets the FDA's dose-optimization requirements under “Project Optimus” and provides a particularly advantageous dataset for regulators.

Inclusion criteria included histologically confirmed advanced solid tumors, ECOG performance status 0-2, a measurable target lesion according to RECIST 1.1 and no previous topoisomerase inhibitor use. Phase Ib patients were required to have received 1–3 previous treatment lines.

BEHOLD-1 Results: What Do the Numbers Tell Us?

Mean follow-up in ovarian cancer was 6.1 months (IQR: 4.7–6.6). Despite this relatively short follow-up, the high response rates show that Mo-Rez acts both rapidly and markedly. The fact that median time to response (TTR) was only 1.4 months is also highly meaningful clinically: given the narrow window for intervention in rapidly progressing disease, such a quick onset of treatment effect could offer a life-saving advantage.

Safety Profile: Are the Side Effects Manageable?

A drug's high efficacy becomes meaningful only with a tolerable safety profile. Global BEHOLD-1 data covering 224 patients showed a generally manageable side-effect profile for Mo-Rez. The most frequently reported side effect was nausea. Grade 3 or higher (serious) side effects included neutropenia (a decrease in neutrophil count), anemia and thrombocytopenia; these findings are consistent with other ADCs containing a topoisomerase I inhibitor. The critically important finding was that the proportion of patients discontinuing treatment because of side effects remained very low , indicating a sustainable safety window that could allow long-term Mo-Rez use.

Does the B7-H4 Expression Level Matter? Efficacy without a Biomarker

Targeted therapy often raises this question: Do only patients with high expression of the target protein respond? This question directly determines both patient selection and drug usability. One of the study's most striking observations emerges here.

According to BEHOLD-1 findings, Mo-Rez, regardless of B7-H4 expression level, showed meaningful antitumor activity. This is extremely important for two reasons. First, B7-H4 is already highly expressed in more than 95% of ovarian and endometrial cancers — so, theoretically, the vast majority fall within the targetable population. Second and more importantly, observing responses in the rare patients with low B7-H4 levels suggests that the drug's mechanism may extend beyond antigen binding to include additional mechanisms such as the “bystander effect” (effects on neighboring cells). The practical consequence is clear: a broader patient population could receive treatment without the need for an expensive, time-consuming biomarker test.

The Scope of the BEHOLD Program: Five Phase III Trials

The strength of the Phase I findings prompted an unusual decision by the developer: without waiting for the Phase II stage, five Phase III trials will be launched directly. This move concretely reflects confidence in the drug's efficacy.

In addition to these five Phase III trials, BEHOLD-2 (NCT06796907), a Phase I/II combination trial, is evaluating Mo-Rez with current standard treatments (including bevacizumab and other agents). The overall program aims to position Mo-Rez in both recurrent/resistant disease and earlier lines of treatment.

GSK's Return to Oncology: A Company's Strategic Transformation

The story of Mo-Rez also describes a fundamental strategic shift by a company, beyond a single drug. In a major portfolio swap with Novartis in 2015, GSK transferred its oncology assets and almost entirely left the field. In recent years, however, a dramatic return has taken place.

At the end of 2023, its deal with the Chinese biotechnology company Hansoh Pharma worth 1.7 billion dollars for the acquisition of Mo-Rez's global rights was one of the most concrete steps in this transformation. As of today, GSK's oncology portfolio includes 4 approved drugs and 13 candidates in clinical development (29 clinical-stage projects in total). The company's 2031 target is 40 billion pounds in annual revenue. For Mo-Rez, 2 billion pounds annually in sales is the expected level.

This development is also strategically critical for closing the gap created when rival AstraZeneca reached 43 billion pounds in revenue in 2025, compared with GSK's 33 billion pounds.

Implications for Practice in Turkey

In Turkey, ovarian cancer is among the cancers in women with the greatest impact on quality of life, and its five-year survival rate remains below 30% at an advanced stage. Endometrial cancer, meanwhile, stands out as a gynecologic malignancy with rising incidence alongside the increasing prevalence of obesity and metabolic syndrome in recent years.

Clinical practice in Turkey for platinum-resistant ovarian cancer and second-line endometrial cancer relies largely on chemotherapy options. Although bevacizumab, PARP inhibitors and immunotherapy combinations are used in certain subgroups, overall response rates remain limited. If Mo-Rez produces positive Phase III results, it will add a new dimension to this situation. Greater participation by Turkey in international clinical trials and broader access to ADC drugs will be two decisive parameters in this process.

This article was created as part of the workflow using various editorial tools, including artificial intelligence. It was reviewed by human editors before publication.